MCRB Stock Overview
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Seres Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.78 |
52 Week High | US$6.87 |
52 Week Low | US$0.73 |
Beta | 2.27 |
1 Month Change | -27.08% |
3 Month Change | -44.27% |
1 Year Change | -86.12% |
3 Year Change | -96.21% |
5 Year Change | -87.81% |
Change since IPO | -98.48% |
Recent News & Updates
Recent updates
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Mar 23Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
Jan 30Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop
Dec 18Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop
Aug 31Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?
Aug 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Dec 28Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
Sep 01Seres Therapeutics: What The Market Is Missing
Aug 19Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M
Aug 03Seres Therapeutics: The Good And The Challenging
Jul 12Seres Therapeutics stock slips on $100M stock offering
Jun 30Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?
Jun 16Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens
Jun 09Seres Therapeutics Is Playing A Long Game
Mar 06Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt
Dec 27Seres Therapeutics Molecular Data On SER-109 Looks Good
Oct 04Seres Therapeutics: Here We Go Again
Sep 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Sep 03Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues
Jul 03Seres Therapeutics (MCRB) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow
Jun 08Seres Therapeutics gets FDA clearance for SER-155 IND trials
Jun 01Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher
May 20Seres Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 05Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?
Apr 05Shareholder Returns
MCRB | US Biotechs | US Market | |
---|---|---|---|
7D | -6.1% | 0.9% | 0.4% |
1Y | -86.1% | 10.3% | 28.8% |
Return vs Industry: MCRB underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: MCRB underperformed the US Market which returned 29.5% over the past year.
Price Volatility
MCRB volatility | |
---|---|
MCRB Average Weekly Movement | 11.5% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MCRB's share price has been volatile over the past 3 months.
Volatility Over Time: MCRB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 233 | Eric Shaff | https://www.serestherapeutics.com |
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection.
Seres Therapeutics, Inc. Fundamentals Summary
MCRB fundamental statistics | |
---|---|
Market cap | US$117.82m |
Earnings (TTM) | -US$113.72m |
Revenue (TTM) | US$126.33m |
0.9x
P/S Ratio-1.0x
P/E RatioIs MCRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MCRB income statement (TTM) | |
---|---|
Revenue | US$126.33m |
Cost of Revenue | US$145.86m |
Gross Profit | -US$19.53m |
Other Expenses | US$94.19m |
Earnings | -US$113.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.75 |
Gross Margin | -15.46% |
Net Profit Margin | -90.02% |
Debt/Equity Ratio | -226.4% |
How did MCRB perform over the long term?
See historical performance and comparison